Ganirelix Injection
Ganirelix
0.25mg
Sun Pharmaceutical Industries Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Indications
Ganirelix Injection is used for:
Ovarian stimulation, Assisted reproduction
Adult Dose
Subcutaneous
Female Infertility
250 mcg SC qDay during mid-to-late follicular phase after initiating follicle-stimulating hormone on day 2 and 3 of the cycle, continue therapy until day of hCG administration
Hepatic impairment: Moderate to severe: Contraindicated.
Child Dose
Renal Dose
Renal impairment: Moderate to severe: Contraindicated.
Administration
Contra Indications
Hypersensitivity, pregnancy, lactation, moderate to severe renal or hepatic impairment.
Precautions
Women with active allergic conditions or a history of allergies.
Lactation: Excretion unknown; not recommended
Pregnancy-Lactation
Interactions
May require dose adjustment of exogenous gonadotropins when concomitantly used during controlled ovarian hyperstimulation.
Adverse Effects
Side effects of Ganirelix :
1-10%
Abdominal pain (1%),Headache (3%),Injection site recation (1%),Nausea (1%),Ovarian hyperstimulation syndrome (2%),Vaginal bleeding (2%),Pelvic pain (5%)
<1%
Anaphylactoid reactions
Mechanism of Action
Ganirelix is a gonadorelin (gonadotrophin-releasing hormone) antagonist. It competitively blocks the gonadotropin-release hormone receptors on the pituitary gonadotroph and transduction pathway. This suppresses gonadotropin secretion and luteinising hormone secretion thus preventing ovulation until the follicles are of adequate size.
Note
Ganirelix 0.25mg Injection manufactured by Sun Pharmaceutical Industries Ltd.. Its generic name is Ganirelix. Ganirelix is availble in Nepal.
Farmaco Nepal drug index information on Ganirelix Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.